An observational study in Cardiomyopathy, Atrial Fibrillation (AF) and Genetic, sponsored by Barts & The London NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Barts & The London NHS Trust · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 51 studies in Cardiomyopathies with a site in United Kingdom — 19 open to participants now, 24 under way, 5 of them phase 3. Cardiomyopathies · United Kingdom.
Among the 51 studies in Cardiomyopathies with a site in United Kingdom, this one is the 12th largest by planned enrollment of the 25 observational ones that give a count, is one of 3 that started in 2026, is one of 25 observational ones, reaches primary completion later than 8 of the 23 other live ones, and was the 49th registered.
556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.
Browse Cardiomyopathies studies →19 of the 51 studies in Cardiomyopathies with a site in United Kingdom are open now. Recruiting first, the newest first:
Lexeo Therapeutics · Sites in United Kingdom, United States, Brazil and 6 more countries
Ages 6+
University of Manchester · Sites in United Kingdom
Ages 18+
Bayer · Sites in United Kingdom, Austria, Belgium and 14 more countries
Ages 18+
Alnylam Pharmaceuticals · Sites in United Kingdom, United States, Argentina and 33 more countries
Ages 18–85
Eidos Therapeutics, a BridgeBio company · Sites in United Kingdom, United States, Argentina and 21 more countries
Ages 18–75
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
51 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 12 · Phase 4 2
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 299 is above the median of 200 across 264 observational studies indexed under Cardiomyopathies.
Median enrollment 137 across the 26 interventional studies, 267 across the 25 observational. Of the 22 that completed or were terminated, 7 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 51 have an industry lead sponsor. The 10 most frequent:
Barts & The London NHS Trust is the lead sponsor of 152 studies on the registry; 22 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Barts & The London NHS Trust has 2 studies filed under Cardiomyopathies — fewer than ten, so there is no comparison to draw.
7 of the studies in Cardiomyopathies with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04520347University of California, Los AngelesIVTCC 2.0: A Prospective Multicenter Ventricular Tachycardia Catheter Ablation Registry | 2026-12 |
| NCT03049254Mayo ClinicMayo AVC Registry and Biobank | 2027-03 |
| NCT06446271NHS Greater Glasgow and ClydeBiomarkers in SCOTland CardiomyopatHy Registry (Bio-SCOTCH) | 2027-03-19 |
| NCT07574697Barts & The London NHS TrustAIC Genotyping Study | 2027-03-31 |
| NCT07852221Insel Gruppe AG, University Hospital BernPatient Selection and Long-Term Outcomes of Pace & Ablate Strategy in Atrial Fibrillation | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 51 studies in Cardiomyopathies with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To quantify genetic variants in a focused DCM gene panel among AF-induced cardiomyopathy (AIC) and positive/negative controls
Atrial Fibrillation (AF) is the most common heart rhythm disorder affecting 1 in 3-5 adults over 45. Although most patients tolerate AF, in some people it can weaken the main pump of the heart (left ventricle), causing heart failure. It is not known why some people develop heart failure during AF and others do not. We propose that individual vulnerability is due to specific genetic abnormalities that do not cause problems until they develop AF. These genetic abnormalities have been identified in patients who develop heart failure with the onset of other stressors, such as alcohol or pregnancy.
Our study will identify 92 patients with AF-triggered heart failure, defined by having heart failure during AF but resolved after the AF was treated using a procedure called catheter ablation. We will measure how common these genetic variations are seen in patients with AF-triggered heart failure and compare them with 184 patients who have AF but don't develop heart failure (negative comparators) and 23 patients who do develop heart failure but do not recover after AF treatment (positive comparators).We shall only test for a limited number of clearly disease-causing genetic variants to ensure cost- effectiveness and minimise the risk of identifying genes of unclear significance.
If we find a genetic association, doctors could: (1) identify patients more likely to develop weakness before the AF becomes persistent, (2) fast-track at-risk patients for catheter ablation treatment, (3) offer family screening where appropriate, and (4) avoid unnecessary testing in low-risk patients. This would directly improve care for people in East London and beyond by personalising AF treatment and preventing avoidable heart failure.
The study population is patients with a diagnosis of persistent AF who have undergone AF CA. Their LVEF at baseline and after CA in Sinus rhythm will determine eligibility. Barts Heart Centre, based at St Bartholomew's Hospital is a tertiary referral centre for cardiac electrophysiology with established expertise in AF CA. This will be the single study site. The team performed approximately 1300 index procedure AF CAs in 2018. Referral for AF CA to Barts Heart Centre is through a 'hub and spoke' arrhythmia service delivery model with its surrounding hospitals. Patients will be referred to the CRF for screening from the Electrophysiology out-patients clinic alongside the referral for AF CA. Vulnerable groups shall be excluded from this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
AIC (Cases):
AF-pEF (Negative controls):
AF/HF non-responders (Positive controls)
EXCLUSION:
AIC (Cases).
AF-pEF (Negative controls)
AF/HF non-responders (Positive controls)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with LVSD during rate-controlled, persistent AF who improve their LVEF after sustained SR is achieved using catheter ablation or cardioversion.
Patients without LVSD during rate-controlled, persistent AF
Patients with LVSD during rate-controlled, persistent AF who do not significantly improve their LVEF after sustained SR is achieved using catheter ablation or cardioversion.
DCM gene prevalence relative to negative control
Group difference between AIC vs AF-pEF in P/LP prevalence from DCM panel
Time frame: On day of baseline testing (1 day)
DCM gene prevalence relative to positive control
Group difference between AIC vs AF/HF non-responders in P/LP prevalence.
Time frame: On day of baseline testing (1 day)
Genotype-recovery time association
Time from durable SR to LVEF normalisation: by genotype (TTNtv; any P/LP): HR from Cox models. Change in LVEF (post-SR minus pre-SR) by genotype: β from linear regression. Rapid recovery proportion (normalisation ≤90 days) by genotype
Time frame: 12 months post-ablation time-point (independent of study enrolment date)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2027, 12 months after the start.
Of 119 non-industry observational studies under Cardiomyopathies, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 34. This study's planned 12 months is below that.
Counting every sponsor, half of 141 studies reached it within 83 months; a quarter within 34.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Barts & The London NHS Trust →